Unichem Laboratories surged 16.36% to Rs 276 after the company reported consolidated net profit of Rs 71.47 crore in Q4 March 2022 as against net loss of Rs 0.41 crore in Q4 March 2021.
On a consolidated basis, net sales rose 34.96% to Rs 369.95 crore in Q4 March 2022 over Q4 March 2021.Profit before tax surged to Rs 57.94 crore in Q4 March 2022 compared with Rs 2.96 crore in Q4 March 2021. Total expense rose 18.10% to Rs 301.52 crore. Cost of material consumed rose 16.53% to Rs 126.69 crore while employee benefits expenses rose 12.49% to Rs 85.54 crore.
For the full year, net profit declined 3.67% to Rs 33.06 crore in the year ended March 2022 as against Rs 34.32 crore during the previous year ended March 2021. Sales rose 2.81% to Rs 1269.83 crore in the year ended March 2022 as against Rs 1235.14 crore during the previous year ended March 2021.
The board recommended dividend of Rs 4 per equity share for the year ended 31 March 2022.
The company reported negative operating cash flow (OCF) of Rs 259.61 crore in the year ended 31 March 2022 compared with positive OCF of Rs 32.98 crore in the year ended March 2021.
Unichem Laboratories is a pharmaceutical company. It addresses the needs of therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app